Built from weaker models, sales multiples or analyst targets, so treat it as a rough guide.
Not used by alerts or posts.
Valued as a pre-revenue company: Net cash floor and Analyst consensus.
ACCE opinionTectonic Therapeutic Inc. Common Stock (TECX)
Fair value
Not available
ACCE price target
$21.00
Rating
Not rated
Horizon
12 months
ACCE price target published on 15 Oct 2026, 00:00 CEST.
Price used: $20.07 at the close on 23 Oct 2026, 22:00 CEST.
Models: Analyst consensus and Net cash floor.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
25
out of 100
Analysts
90% buy
10 covering
1-year return
+15.4%
Dividend yield
0.00%
Tectonic Therapeutic Inc. Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
I don't have a product description for Tectonic Therapeutic in the data provided, so I can't say what it develops or what its lead programs are. The available figures are thin: zero revenue growth, zero margins, a PE of zero, and an ROE of -33.8%, which points to a company that is still spending heavily without earnings to offset it. The 27/100 score and absence from any index put it in the speculative tail of healthcare, with a $416M market cap that leaves little room for a clinical or regulatory setback to go unnoticed. Before this merits a deeper look, we need the pipeline, cash runway and next data readout from the filings, since none of those are in this dataset.